Full Year 2025 results

AI SummaryClose X

Novacyt S.A. reported full-year 2025 results with statutory revenue of £20.0 million, a slight increase from £19.6 million in 2024, exceeding market expectations. The company saw growth in its Clinical segment to £13.8 million and a significant 25% increase in its Instrumentation segment to £2.5 million, driven by the launch of the LightBench® Discover instrument. However, the RUO segment declined by approximately 10% to £3.7 million. The Group's EBITDA loss improved to £7.8 million from £9.1 million in the prior year, and the loss after tax decreased to £22.9 million from £41.8 million. The cash position at year-end 2025 was £19.1 million. Post-period, Novacyt acquired Southern Cross Diagnostics for approximately £4.4 million and raised €0.8 million through a rights issue.

Disclaimer*

UK 100

Latest directors dealings